Scholarlink

<p>Attention-deficit hyperactivity disorder (ADHD) co-occurring with substance use disorder (SUD) is highly prevalent and is associated with poor prognosis and negative treatment outcomes. Comprehensive management of ADHD-SUD comorbidity involves pharmacotherapy integrated with psychotherapy to enhance treatment retention and success. Psychostimulants are the mainstay of ADHD pharmacotherapy and do not exacerbate SUD symptoms; however, psychostimulants are associated with an inherent risk of misuse, abuse and diversion. Cognitive behavioural therapy is a first-line behavioural intervention that teaches patients harm reduction and coping skills while addressing affective and environmental risks for substance use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treat comorbid attention-deficit hyperactivity disorder and substance use disorder with both pharmacotherapy and psychotherapy for best results

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Kimberley Chen,
  • Connie Kang

摘要

Attention-deficit hyperactivity disorder (ADHD) co-occurring with substance use disorder (SUD) is highly prevalent and is associated with poor prognosis and negative treatment outcomes. Comprehensive management of ADHD-SUD comorbidity involves pharmacotherapy integrated with psychotherapy to enhance treatment retention and success. Psychostimulants are the mainstay of ADHD pharmacotherapy and do not exacerbate SUD symptoms; however, psychostimulants are associated with an inherent risk of misuse, abuse and diversion. Cognitive behavioural therapy is a first-line behavioural intervention that teaches patients harm reduction and coping skills while addressing affective and environmental risks for substance use.